← Sichuan Kelun Pharmaceutical overview

Sichuan Kelun Pharmaceutical vs China Resources Double-Crane Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Sichuan Kelun Pharmaceutical Co Ltd (002422.CS)

Q3 2026
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.

September 2026
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.

Latest
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.

China Resources Double-Crane Pharmaceutical Co Ltd (600062.CG)

Q3 2026
▲3▼1

Double-Crane bets on Lier Chemical while earnings slip and drug pipeline grows

  • 5.66 billion yuan Lier Chemical acquisition Double-Crane won the bid to buy 23.5% of Lier Chemical for 5.656 billion yuan cash, becoming its controlling shareholder. This expands into pesticides and synthetic biology, a long-term growth bet, though it uses a lot of cash and is a major restructuring.

    This is the biggest new event of the period and the main force behind the stock's story.

  • Interim profit and revenue fall First-half 2026 net profit was 946 million yuan, down 3.43%, and revenue fell 3.44% to 5.615 billion yuan. This shows the core business is under pressure, a real counterweight to the acquisition and pipeline news.

    It is the key financial result of the period and the main negative force on the stock.

  • New drug approvals and trial progress The company completed a Phase III trial for pregabalin extended-release tablets and received approvals for acetazolamide capsules, sodium lactate Ringer's irrigation solution, lomustine capsules, and ezetimibe/atorvastatin tablets. These add future revenue sources.

    A steady stream of pipeline wins supports long-term growth even as current earnings dip.

  • Dividend and procurement selection Double-Crane paid a cash dividend of 3.79 yuan per 10 shares and had products proposed for selection in the 12th national centralized drug procurement. Both are shareholder-friendly and support sales volume, though price cuts from procurement can pressure margins.

    These are new capital-return and demand-side events that affect investor income and product demand.

August 2026
▲3▼1

Double-Crane bets on Lier Chemical while earnings slip and drug pipeline grows

  • 5.66 billion yuan Lier Chemical acquisition Double-Crane won the bid to buy 23.5% of Lier Chemical for 5.656 billion yuan cash, becoming its controlling shareholder. This expands into pesticides and synthetic biology, a long-term growth bet, though it uses a lot of cash and is a major restructuring.

    This is the biggest new event of the period and the main force behind the stock's story.

  • Interim profit and revenue fall First-half 2026 net profit was 946 million yuan, down 3.43%, and revenue fell 3.44% to 5.615 billion yuan. This shows the core business is under pressure, a real counterweight to the acquisition and pipeline news.

    It is the key financial result of the period and the main negative force on the stock.

  • New drug approvals and trial progress The company completed a Phase III trial for pregabalin extended-release tablets and received approvals for acetazolamide capsules, sodium lactate Ringer's irrigation solution, lomustine capsules, and ezetimibe/atorvastatin tablets. These add future revenue sources.

    A steady stream of pipeline wins supports long-term growth even as current earnings dip.

  • Dividend and procurement selection Double-Crane paid a cash dividend of 3.79 yuan per 10 shares and had products proposed for selection in the 12th national centralized drug procurement. Both are shareholder-friendly and support sales volume, though price cuts from procurement can pressure margins.

    These are new capital-return and demand-side events that affect investor income and product demand.

Latest
▲3▼1

Double-Crane bets on Lier Chemical while earnings slip and drug pipeline grows

  • 5.66 billion yuan Lier Chemical acquisition Double-Crane won the bid to buy 23.5% of Lier Chemical for 5.656 billion yuan cash, becoming its controlling shareholder. This expands into pesticides and synthetic biology, a long-term growth bet, though it uses a lot of cash and is a major restructuring.

    This is the biggest new event of the period and the main force behind the stock's story.

  • Interim profit and revenue fall First-half 2026 net profit was 946 million yuan, down 3.43%, and revenue fell 3.44% to 5.615 billion yuan. This shows the core business is under pressure, a real counterweight to the acquisition and pipeline news.

    It is the key financial result of the period and the main negative force on the stock.

  • New drug approvals and trial progress The company completed a Phase III trial for pregabalin extended-release tablets and received approvals for acetazolamide capsules, sodium lactate Ringer's irrigation solution, lomustine capsules, and ezetimibe/atorvastatin tablets. These add future revenue sources.

    A steady stream of pipeline wins supports long-term growth even as current earnings dip.

  • Dividend and procurement selection Double-Crane paid a cash dividend of 3.79 yuan per 10 shares and had products proposed for selection in the 12th national centralized drug procurement. Both are shareholder-friendly and support sales volume, though price cuts from procurement can pressure margins.

    These are new capital-return and demand-side events that affect investor income and product demand.